Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|April 20, 2006
Cardinal Health Names R. Kerry Clark President, CEO, and Director
Cardinal Health, Inc., (Dublin, OH, www.cardinalhealth.com) has appointed R. Kerry Clark as president, chief executive officer, and a member of its board of directors. Clark succeeds company founder Robert D. Walter as chief executive.
Advertisement
Cardinal Health, Inc., (Dublin, OH,
Since 2002, Clark served as vice chairman of the board of The Procter & Gamble Company, where he was responsible for its $20 billion Global Family Health business, including pharmaceuticals and over-the-counter medicines. He acquired strategic, operational, and corporate management experience in leadership positions in North America and Asia during his 32 years with Procter & Gamble.
Cardinal Health, Inc. is a $75 billion, global company serving the healthcare industry with a broad portfolio of products and services. It manufactures, packages, and distributes pharmaceuticals and medical supplies, offers a range of clinical services, and develops automation products to improve the management and delivery of supplies and medication for hospitals, physician offices, and pharmacies.
Advertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement